跳至主要内容
临床试验/RBR-2fw8kg
RBR-2fw8kg尚未招募4 期

Pilot study of the effects of Cannabidiol in patients with Generalized Anxiety Disorder compared to the effects of Clonazepan

Faculdade de Medicina de Ribeirão Preto - USP0 个研究点开始时间: 2020年8月7日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 60Y(—)

入选标准

  • Diagnosis of Generalized Anxiety Disorder (from SCID-5-CV); both sexes, education above eight years; age between 18 and 60 years; total score greater than or equal to 20 on the Hamilton Rating Scale for Anxiety (HAMA); total score greater than or equal to the Global Clinical Impression - Severity scale (CGI-S); total score greater than or equal to 17 on the Hamilton Depression Rating Scale (HAMD17).

排除标准

  • Presence of general medical condition; history of neurological disease (except headache); current or past diagnosis of psychoactive substance abuse or use in the past three months; psychotic conditions of any nature according to SCID-5_CV throughout life; other psychiatric diagnoses in addition to generalized anxiety disorder in the last 6 months (except for past remitted depression, social phobia and / or specific phobias); suicide risk (including suicide attempt in the last 1 year); history of previous drug treatment for generalized anxiety disorder; hx of allergy or idiosyncratic reactions to Cannabis sativa derivatives.

研究者

发起方
Faculdade de Medicina de Ribeirão Preto - USP

相似试验

Initial study of the effects of cannabidiol in... | 临床试验